It is about a multicentric study prospective of more than patients' 60 years with a thrombopenia isolated of less than 100 G/L blood platelet without cause found to estimate so certain examinations realized in the diagnosis (medullary cytogenetics, dosage of the TPO, the Anti-platelet antibodies, isotopic lifetime of platelet) are in favour of the diagnosis of PTI.
It is about a multicentric study prospective of more than patients' 60 years with a thrombopenia isolated of less than 100 G/L blood platelet without cause found to estimate so certain examinations realized in the diagnosis (medullary cytogenetics, dosage of the TPO, the Anti-platelet antibodies, isotopic lifetime of platelet) are in favour of the diagnosis of PTI. The principal endpoint is to evaluate if the medullary cytogenetics is the predictive factor of the diagnosis of PTI in front of a thrombopenia isolated in elderly. The secondary endpoints are : * to identify at the time of the diagnosis, the factors and/or predictive markers correlated in the final diagnosis of PTI or SMD * to study the respective frequency of the PTI and the SMD in front of a thrombopenia seemingly isolated of the subject of more than 60 years. 200 patients will be included. 160 patients should be assessable at the end of study by considering the excluded patients, the dead and the lost sight.They will be followed every 4 months, during two years. In every visit, will be realized a clinical examination, a blood film, a haemogram. If the haemogram is abnormal, a bone marrow biopsy is realized. The patient who presents a myelodysplastic syndrome is excluded.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
200
Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet. The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal.
CHU Amiens
Amiens, France
RECRUITINGthe result of cytogenetics medullary
the primary endpoint corresponds to the occurence of the PTI after two years after inclusion.
Time frame: two years after inclusion
dosage of the TPO
Time frame: EVERY 4 MONTHS (followed every four months during two years apres inclusion)
the result to the antibodies antiplatelet (positive or negative) for MAIPA
Time frame: EVERY 4 MONTHS (followed every 4 months during two years after the inclusion)
The isotopic lifetime of platelet
\< or \> 3.5 days
Time frame: EVERY 4 MONTHS (followed every four months during two years apres inclusion)
The test in corticoids by the prednisone per os
1 mg / kg / day for 3 weeks The therapeutic test is considered as positive if a number of platelets is \> 50 G/l with at least a doubling of the platelet rate before treatment
Time frame: EVERY 4 MONTHS (followed every 4 months during two years after the inclusion)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.